title: [Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
abstract: OBJECTIVE
  Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. This article analyzed the efficacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC.
  
  
  METHODS
  We retrospectively analyzed the short-term efficacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed.
  
  
  RESULTS
  Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). The overall response rate was 5.9%, and the disease control rate was 47.1%. The median progression-free survival was 4.4 months (95%CI: 4.05-7.46). The main grade 3/4 toxicity was hand-foot skin reaction.
  
  
  CONCLUSIONS
  Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.
authors.affiliation: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
authors.forename: Puyuan
authors.initials: P
authors.lastname: Xing
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage*; D012189:Retrospective Studies; D000077210:Sunitinib; D015996:Survival Rate
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D007211:Indoles; D011758:Pyrroles; D017239:Paclitaxel; D000077210:Sunitinib